Pre-surgery hormone therapy to guide radiation decisions for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether taking hormone therapy for 3 months before breast-conserving surgery can help doctors decide if radiation is right for you. It is for women aged 65 and older with a common type of breast cancer that is hormone receptor-positive and HER2-negative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 or older
- Your breast cancer must be hormone receptor-positive (ER+ and/or PR+) and HER2-negative
- Your cancer should not have spread to lymph nodes in the armpit
- You must be planning to have breast-conserving surgery (lumpectomy)
- You must be a candidate for radiation therapy and hormone therapy (tamoxifen or an aromatase inhibitor)
- You must be able to take pills and agree to take hormone therapy for 3 months before your surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This study looks at how a hormone-blocking medicine (endocrine therapy) given before surgery affects a marker called Ki67 in your breast cancer cells. The goal is to see if the medicine can slow the growth of the cancer, which may help doctors choose the best treatment for you.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.